MERAL KURT

MERAL KURT serves as an Associate Professor in the Department of Radiation Oncology at Bursa Uludag University Faculty of Medicine, a position she has held since 2010 following promotion from Assistant Professor (2007). Her clinical expertise spans advanced radiotherapy techniques for genitourinary and gastrointestinal malignancies, with significant contributions to multi-institutional Turkish Society for Radiation Oncology (TROD) studies.

Education:

• Bursa Çelebi Mehmet High School (1988)
• Uludağ University Faculty of Medicine (MD, 1994)

Research Focus: Dr. Kurt's work centers on optimizing radiotherapy for oligometastatic disease and dosimetric comparisons of advanced techniques including CyberKnife, VMAT, and stereotactic body radiation therapy (SBRT). Her investigations cover prostate, bladder, colorectal, esophageal, and rectal cancers, with emphasis on survival outcomes, treatment toxicity, and predictive nomograms for personalized therapy. Recent studies analyze SBRT efficacy in oligometastatic prostate cancer and dosimetric advantages of robotic radiosurgery systems.

Publication Trends: Analysis of her 134 Web of Science publications reveals a strong shift toward multi-institutional clinical trials (2022-2025), particularly TROD studies examining radiotherapy's role in rare cancers like cervical esophageal carcinoma. Her work increasingly integrates machine learning for prognostic modeling while maintaining technical rigor in dosimetric evaluations across diverse cancer types.

Professional Recognition:

• Specialist Qualification Certificate, Turkish Radiation Oncology Association (2010, renewed 2020)

Academic Contributions: Dr. Kurt teaches radiotherapy courses for 2nd- and 5th-year medical students, radiotherapy technicians, and Health Physics Master's students, focusing on genitourinary and gastrointestinal system cancers. She has advised 3 graduate theses and contributed to institutional accreditation as a member of Uludağ University's Health Application and Research Center Accreditation Board (2005-2007).

Collaborative Networks: She actively participates in TROD research groups and leads multi-center analyses on oligometastatic disease treatment, maintaining strong ties with the University of Kentucky (where she completed fellowship training) and domestic oncology centers through the Turkish Radiation Oncology Association.